Proinflammatory CD20+ T cells in the pathogenesis of multiple sclerosis
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Proinflammatory CD20+ T cells in the pathogenesis of multiple sclerosis. / von Essen, Marina R; Ammitzbøll, Cecilie; Hansen, Rikke H; Petersen, Eva R S; McWilliam, Oskar; Marquart, Hanne V.; Damm, Peter; Sellebjerg, Finn.
In: Brain, Vol. 142, No. 1, 2019, p. 120-132.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Proinflammatory CD20+ T cells in the pathogenesis of multiple sclerosis
AU - von Essen, Marina R
AU - Ammitzbøll, Cecilie
AU - Hansen, Rikke H
AU - Petersen, Eva R S
AU - McWilliam, Oskar
AU - Marquart, Hanne V.
AU - Damm, Peter
AU - Sellebjerg, Finn
PY - 2019
Y1 - 2019
N2 - With the discovery that the highly effective anti-CD20 antibody therapies developed to deplete CD20+ B cells deplete CD20+ T cells equally well, a great interest in the biological properties of CD20+ T cells has emerged. In this study we show that CD20+ T cells have a proinflammatory Th1/Tc1 phenotype with a high proliferative capacity to CNS antigens. We also found that the percentage of CD20+ T cells is increased in the blood of patients with multiple sclerosis and are enriched in the CSF of the patients. Furthermore, we found a positive correlation between CD20+ T cells in the CSF and multiple sclerosis disease severity and see that regulation of CD20+ T cells likely contributes to the positive treatment effect of the multiple sclerosis treatment alemtuzumab. These data represent an important contribution to the understanding of the nature of CD20+ T cells and strongly suggests a role of CD20+ T cells in the pathogenesis of multiple sclerosis.
AB - With the discovery that the highly effective anti-CD20 antibody therapies developed to deplete CD20+ B cells deplete CD20+ T cells equally well, a great interest in the biological properties of CD20+ T cells has emerged. In this study we show that CD20+ T cells have a proinflammatory Th1/Tc1 phenotype with a high proliferative capacity to CNS antigens. We also found that the percentage of CD20+ T cells is increased in the blood of patients with multiple sclerosis and are enriched in the CSF of the patients. Furthermore, we found a positive correlation between CD20+ T cells in the CSF and multiple sclerosis disease severity and see that regulation of CD20+ T cells likely contributes to the positive treatment effect of the multiple sclerosis treatment alemtuzumab. These data represent an important contribution to the understanding of the nature of CD20+ T cells and strongly suggests a role of CD20+ T cells in the pathogenesis of multiple sclerosis.
KW - Adult
KW - Alemtuzumab/therapeutic use
KW - Antigens, CD20/blood
KW - Cell Proliferation/drug effects
KW - Cytokines/metabolism
KW - Female
KW - Flow Cytometry
KW - Humans
KW - Male
KW - Middle Aged
KW - Multiple Sclerosis/blood
KW - Multiple Sclerosis, Chronic Progressive/blood
KW - T-Lymphocytes/drug effects
KW - Young Adult
U2 - 10.1093/brain/awy301
DO - 10.1093/brain/awy301
M3 - Journal article
C2 - 30561509
VL - 142
SP - 120
EP - 132
JO - Brain
JF - Brain
SN - 0006-8950
IS - 1
ER -
ID: 237654017